Xtant Medical’s second-quarter sales reached $35.4 million, according to financial results posted Aug. 12.
Five notes:
1. Revenue grew 18% year over year, according to a news release.
2. The company saw net income of $3.6 million compared to a net loss of $3.9 million in the same time in 2024.
3. Highlights of the second quarter include plans to sell two spine implant lines to Companion Spine for about $19.2 million and the launch of OsteoFactor Pro.
4. Operating expenses decreased compared to the same period in 2024. Second-quarter expenses were $19.7 million in 2025 compared to $21.5 million in 2024.
5. Xtant Medical raised its 2025 guidance and expects full-year revenue to reach $131 million to $135 million.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.